Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Nov 6, 2013; 4(4): 120-126
Published online Nov 6, 2013. doi: 10.4292/wjgpt.v4.i4.120
Published online Nov 6, 2013. doi: 10.4292/wjgpt.v4.i4.120
Figure 1 Flow diagram of follow-up.
1Between 12 and 48 mo, 9 patients had antireflux treatment: 8 patients underwent antireflux surgery and 1 an alternative endoscopic treatment.
Figure 2 Medication use at 3 mo after endocinch and at the end of follow-up.
Presented as percentage of the baseline dose. Interquartile range (IQR) , range and median are shown; Median values were 31% and 97% for 3 mo and end of follow-up, respectively (bP < 0.001, dP < 0.001, both compared with baseline).
Figure 3 Kaplan-Meier survival curves.
Analysis of proportion of patients responding to Endocinch during follow-up; All treatment failures (i.e., > 50% of baseline acid-suppressive dose or other antireflux treatment) were included.
- Citation: Schwartz MP, Schreinemakers JRC, Smout AJPM. Four-year follow-up of endoscopic gastroplication for the treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2013; 4(4): 120-126
- URL: https://www.wjgnet.com/2150-5349/full/v4/i4/120.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v4.i4.120